• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Gilead Sciences Inc.

    11/13/24 5:13:05 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GILD alert in real time by email
    FWP 1 tm2426602d3_fwp.htm FWP

     

    Free Writing Prospectus

    Filed Pursuant to Rule 433

    Registration Statement No. 333-273745

    November 13, 2024

     

    GILEAD SCIENCES, INC.

     

     

    PRICING TERM SHEET

    4.80% SENIOR NOTES DUE 2029
    5.10% SENIOR NOTES DUE 2035

    5.50% SENIOR NOTES DUE 2054

    5.60% SENIOR NOTES DUE 2064

     

    Issuer:  

    Gilead Sciences, Inc. (the “Company”)

     

    Title of Security:

    4.80% Senior Notes due 2029 (the “2029 Notes”)

    5.10% Senior Notes due 2035 (the “2035 Notes”)

    5.50% Senior Notes due 2054 (the “2054 Notes”)

    5.60% Senior Notes due 2064 (the “2064 Notes”)

     

    Principal Amount:

    2029 Notes: $750,000,000

    2035 Notes: $1,000,000,000

    2054 Notes: $1,000,000,000

    2064 Notes: $750,000,000

     

    Trade Date:

    November 13, 2024

     

    Settlement Date:            

    November 20, 2024 (T+5)

     

    It is expected that delivery of the notes will be made against payment therefor on or about November 20, 2024, which is the fifth business day following the date of the pricing of the notes (T+5). Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day unless the parties to that trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on or after the date of pricing but prior to the closing date may be required, by virtue of the fact that the notes initially will settle in T+5, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement and should consult their own advisers.

     

     

     

     

    Maturity Date:

    2029 Notes: November 15, 2029

    2035 Notes: June 15, 2035

    2054 Notes: November 15, 2054

    2064 Notes: November 15, 2064

     

    Price to Public:

     

    2029 Notes: 99.988% of the principal amount

    2035 Notes: 99.599% of the principal amount

    2054 Notes: 99.709% of the principal amount

    2064 Notes: 99.290% of the principal amount

       
    Yield to Maturity:

    2029 Notes: 4.803%

    2035 Notes: 5.149%

    2054 Notes: 5.520%

    2064 Notes: 5.649%

     

    Spread to Benchmark Treasury:

     

    2029 Notes: 50 basis points

    2035 Notes: 70 basis points

    2054 Notes: 87.5 basis points

    2064 Notes: 100 basis points

     

    Benchmark Treasury:

     

    2029 Notes: 4.125% due October 31, 2029

    2035 Notes: 4.250% due November 15, 2034

    2054 Notes: 4.250% due August 15, 2054

    2064 Notes: 4.250% due August 15, 2054

       
    Benchmark Treasury Price / Yield:

    2029 Notes: 99-06 ¾ / 4.303%

    2035 Notes: 98-13 / 4.449%

    2054 Notes: 93-21 / 4.645%

    2064 Notes: 93-21 / 4.645%

     

    Interest Payment Dates:  

     

    2029 Notes: May 15 and November 15, commencing May 15, 2025

    2035 Notes: June 15 and December 15, commencing June 15, 2025

    2054 Notes: May 15 and November 15, commencing May 15, 2025

    2064 Notes: May 15 and November 15, commencing May 15, 2025

     

    Optional Redemption:  

    Make-Whole Call:

     

    2029 Notes: T+10 basis points, prior to October 15, 2029 (assuming the notes called for redemption matured on October 15, 2029)

    2035 Notes: T+15 basis points, prior to March 15, 2035 (assuming the notes called for redemption matured on March 15, 2035)

    2054 Notes: T+15 basis points, prior to May 15, 2054 (assuming the notes called for redemption matured on May 15, 2054)

    2064 Notes: T+15 basis points, prior to May 15, 2064 (assuming the notes called for redemption matured on May 15, 2064)

     

    Par Call:

     

    2029 Notes: At 100%, on or after October 15, 2029

    2035 Notes: At 100%, on or after March 15, 2035

    2054 Notes: At 100%, on or after May 15, 2054

    2064 Notes: At 100%, on or after May 15, 2064

     

     

     

     

    CUSIP / ISIN:

    2029 Notes: 375558 CB7 / US375558CB72

    2035 Notes: 375558 CC5 / US375558CC55

    2054 Notes: 375558 CD3 / US375558CD39

    2064 Notes: 375558 CE1 / US375558CE12

     

    Day Count Convention:

    360-day year consisting of twelve 30-day months

     

    Joint Book-Running Managers:

    Barclays Capital Inc.

    BofA Securities, Inc.

    Citigroup Global Markets Inc.

    Goldman Sachs & Co. LLC

    HSBC Securities (USA) Inc.

    J.P. Morgan Securities LLC

    Mizuho Securities USA LLC

    Morgan Stanley & Co. LLC

    RBC Capital Markets, LLC

    SG Americas Securities, LLC

    TD Securities (USA) LLC

    U.S. Bancorp Investments, Inc.

    Wells Fargo Securities, LLC

     

    Senior Co-Managers:

    Blaylock Van, LLC

    Siebert Williams Shank & Co., LLC

     

    Junior Co-Managers:

    American Veterans Group, PBC

    Independence Point Securities LLC

    Loop Capital Markets LLC

    Samuel A. Ramirez & Company, Inc.

     

     

    *      *      *

     

    The issuer has filed a registration statement (including a prospectus) and a prospectus supplement with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the prospectus supplement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. toll-free at 1-888-603-5847 or calling BofA Securities, Inc. toll free at 1-800-294-1322.

     

    This pricing term sheet supplements the Preliminary Prospectus Supplement filed by Gilead Sciences, Inc. on November 13, 2024 relating to its Prospectus dated August 4, 2023.

     

     

     

    Get the next $GILD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GILD

    DatePrice TargetRatingAnalyst
    1/7/2026$145.00Buy
    UBS
    11/24/2025$140.00Buy
    Truist
    11/13/2025$140.00Sector Outperform
    Scotiabank
    8/19/2025$128.00Neutral → Outperform
    Daiwa Securities
    8/8/2025$127.00Hold → Buy
    Truist
    7/25/2025$133.00Hold → Buy
    Needham
    4/22/2025$125.00Overweight
    Cantor Fitzgerald
    3/4/2025$115.00 → $132.00Outperform
    Oppenheimer
    More analyst ratings

    $GILD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO O'Day Daniel Patrick exercised 115,640 shares at a strike of $66.01 and sold $17,346,000 worth of shares (115,640 units at $150.00) (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/6/26 4:22:37 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Comm & Corp Aff Officer Mercier Johanna was granted 44,867 shares and covered exercise/tax liability with 24,800 shares, increasing direct ownership by 19% to 123,288 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/5/26 6:51:29 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Dickinson Andrew D was granted 44,867 shares and covered exercise/tax liability with 24,802 shares, increasing direct ownership by 13% to 170,568 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/5/26 6:49:59 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA Approves Label Update for Kite's Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma

    – Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified – Kite, a Gilead Company (NASDAQ:GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous Limitations of Use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL). The updated label reinforces the robust safety data of Yescarta in eligible patients with R/R PCNSL; Yescarta is the only CAR T-cell therapy approved for R/R large B-cell lymphoma to have this Limitations of Use removed.

    2/6/26 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a health

    1/27/26 4:05:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

    – Combination Reduced the Risk of Death or Disease Progression by 35% Versus Standard of Care in Frontline PD-L1+ Metastatic TNBC Setting – Gilead Sciences, Inc. (NASDAQ:GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). ASCENT-04 successfully met its primary endpoint of progression-free survival (PFS) with a 35% (HR: 0.65; p<0.001) reduced risk of disease progression or death for Trodelvy plus Keytruda (n=221) versus

    1/21/26 5:00:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Gilead Sciences Inc.

    SCHEDULE 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/5/26 1:23:14 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Gilead Sciences Inc.

    144 - GILEAD SCIENCES, INC. (0000882095) (Subject)

    11/28/25 1:02:54 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

    11/19/25 8:30:34 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Gilead Sciences with a new price target

    UBS resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $145.00

    1/7/26 9:10:38 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist resumed coverage on Gilead Sciences with a new price target

    Truist resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $140.00

    11/24/25 8:41:38 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scotiabank initiated coverage on Gilead Sciences with a new price target

    Scotiabank initiated coverage of Gilead Sciences with a rating of Sector Outperform and set a new price target of $140.00

    11/13/25 9:13:18 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)

    2/13/24 5:48:49 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/9/24 6:21:28 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 3:32:27 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Gilead Sciences Inc.

    SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 2:49:26 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Leadership Updates

    Live Leadership Updates

    View All

    Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par

    12/18/25 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

    4/28/25 4:05:00 PM ET
    $CTNM
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $GILD
    Financials

    Live finance-specific insights

    View All

    Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a health

    1/27/26 4:05:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

    Arrivals of the twice-yearly PrEP option in Eswatini and Zambia mark an important milestone in the goal of ending the HIV epidemic in sub-Saharan Africa Gilead Sciences, Inc. (NASDAQ:GILD) today announced the delivery of first shipments of lenacapavir – Gilead's twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people living with HIV globally. "The arrivals of the first doses of lenacapavir in Eswatini and Zambia mark an im

    11/18/25 5:00:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company's twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure prophylaxis (PrEP) for the prevention of HIV. The award, which recognizes outstanding pharmaceutical products for their contributions to improving human health, is a testament to Gilead's long-standing commitment to HIV innovation. HIV continues to pose a formidable global health challenge, with 1.3 million new infections occurring

    10/31/25 8:00:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care